drugset
drugset / Trial / NCT01280786

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01280786 ↗

Phase 1 Unknown 36 enrolled Synta Pharmaceuticals Corp.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.

Timeline

Start
2011-01
Primary completion
2014-06
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Elesclomol Small molecule — Intravenous

Indications

acute myeloid leukemia